Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment
- PMID: 20527227
- PMCID: PMC2933750
Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment
Abstract
Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United States. In 2008, approximately 40,000 cases were newly diagnosed. Although the majority of these cancers are curable by means of hysterectomy and radiotherapy, a subset of endometrial tumors exhibits an aggressive phenotype characterized by lymphovascular invasion, high histological grade, and myometrial invasion, leading to poor prognosis. The mechanisms involved in this aggressive transformation are largely unknown, however, interactions between the primary tumor mass and the surrounding stroma likely play a role in this transformation. Despite the fact that research in other common malignancies has elucidated important associations between stromal protein expression and invasion, these mechanisms have been poorly explored in the area of endometrial cancer. In fact, few investigations have been conducted in the area of tumor microenvironment for endometrial tumors. Invasion and metastasis are two primary reasons for treatment failure related to endometrial cancer. Expression of stromal-derived proteins can potentially serve as biomarkers of aggressive disease as well as biomarkers for remission monitoring. In order to study how expression of these proteins relates to the prognosis of endometrial cancer, these proteins need to be explored in large sets of existing data and/or tissue banks. In this paper, we briefly review the role of three stromal related pathways, SDF-1alpha/CXCR4, HGF/c-Met, and VEGF-A in endometrial cancer prognosis as an overview of the literature. We report that the role of SDF-1alpha/CXCR4 and HGF/c-Met in endometrial cancer prognosis remains unclear, whereas the evidence pertaining to VEGF indicates that overexpression is involved in tumor growth and metastasis. Finally, we would like to highlight the need to explore stromal proteins as a potential tool for the detection of aggressive endometrial tumors and explore some of the molecular approaches that can be utilized in the exploration of the tumor environment.
Conflict of interest statement
No conflict of interest declared
Similar articles
-
Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer.J Clin Endocrinol Metab. 2002 May;87(5):2376-83. doi: 10.1210/jcem.87.5.8483. J Clin Endocrinol Metab. 2002. PMID: 11994390
-
Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.J Obstet Gynaecol. 2018 Jan;38(1):96-102. doi: 10.1080/01443615.2017.1328591. Epub 2017 Aug 1. J Obstet Gynaecol. 2018. PMID: 28764605
-
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.Mod Pathol. 2008 Jul;21(7):912-23. doi: 10.1038/modpathol.2008.82. Epub 2008 May 16. Mod Pathol. 2008. PMID: 18487993
-
Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study.Cytokine. 2013 Nov;64(2):509-15. doi: 10.1016/j.cyto.2013.07.024. Epub 2013 Aug 25. Cytokine. 2013. PMID: 23985752
-
HGF and c-Met in pathogenesis of endometrial carcinoma.Front Biosci (Landmark Ed). 2015 Jan 1;20(4):635-43. doi: 10.2741/4328. Front Biosci (Landmark Ed). 2015. PMID: 25553470 Review.
Cited by
-
Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.Front Oncol. 2022 Jun 2;12:923641. doi: 10.3389/fonc.2022.923641. eCollection 2022. Front Oncol. 2022. PMID: 35719911 Free PMC article.
-
Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.Oncotarget. 2015 Apr 30;6(12):10634-45. doi: 10.18632/oncotarget.3521. Oncotarget. 2015. PMID: 25860936 Free PMC article.
-
Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.Horm Cancer. 2015 Aug;6(4):131-41. doi: 10.1007/s12672-015-0223-4. Epub 2015 May 15. Horm Cancer. 2015. PMID: 25976290 Free PMC article.
-
MicroRNAs in gynecological cancers: Small molecules with big implications.Cancer Lett. 2017 Oct 28;407:123-138. doi: 10.1016/j.canlet.2017.05.011. Epub 2017 May 24. Cancer Lett. 2017. PMID: 28549791 Free PMC article. Review.
-
Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities.J Immunother Cancer. 2022 Feb;10(2):e003833. doi: 10.1136/jitc-2021-003833. J Immunother Cancer. 2022. PMID: 35115363 Free PMC article.
References
-
- West RB, van de Rijn M. Experimental approaches to the study of cancer-stroma interactions: recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest. 2007 Oct;87(10):967–70. - PubMed
-
- Anton K, Glod J. Targeting the tumor stroma in cancer therapy. Curr Pharm Biotechnol. 2009 Feb;10(2):185–91. - PubMed
-
- NCI. EGRP Hosts Workshop on Understudied Rare Cancers. [cited 2009 July 2, 2009]; Available from: http://epi.grants.cancer.gov/Conference2/appendices.html#b.
-
- Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007 Jan;62(1):28–34. discussion 5–6. - PubMed
-
- Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, et al. Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy. Cell Cycle. 2009 Jun 1;8(11):1654–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous